CD8A and myeloid sarcoma: Only the combinatory analysis of the CD8α and CD8β chain along with CD45RA, CCR7+, CD27 and CD28 marker analysis was able to segregate CD8 phenotypes in patients with MS from CD8+T-cells from healthy blood donors.